Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark N Milton

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Ebiomedicine|May 13, 2025
An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesBeryl B Cummings, Page R Bouchard, Mark N Milton, et al.
Lancet (London, England)|May 18, 2025
Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studiesBeryl B Cummings, Mark P Joing, Page R Bouchard, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Ebiomedicine|May 13, 2025
An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesBeryl B Cummings, Page R Bouchard, Mark N Milton, et al.
Lancet (London, England)|May 18, 2025
Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studiesBeryl B Cummings, Mark P Joing, Page R Bouchard, et al.
Pageof 2